- Home
- RPAY vs ACIU Comparison
RPAY vs ACIU Comparison
Compare RPAY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | ACIU |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.0M | 247.6M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RPAY | ACIU |
|---|---|---|
| Price | $3.86 | $2.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $5.53 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 403.4K | 224.6K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $309,261,000.00 | N/A |
| Revenue This Year | $12.54 | $706.75 |
| Revenue Next Year | $4.66 | $321.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $2.10 |
| 52 Week High | $5.89 | $4.00 |
Technical Indicators
Market Signals| Indicator | RPAY | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 64.88 |
| Support Level | $3.53 | $2.57 |
| Resistance Level | $3.91 | $3.00 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 75.68 | 86.73 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.
About ACIU AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.